s doctors, scientists, and investors try to pick apart which powerful cancer immunotherapy is the best bet for patients, there’s an emerging new tool that might clear up the fog around a whole class of medicines — if its predictive promise can be confirmed in large clinical trials.

It’s called tumor mutation burden, or TMB, and it’s essentially a measure of just how unique a patient’s cancer might be. It could also help doctors identify which patients might benefit from immunotherapies called checkpoint inhibitors.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.